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Abstract
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently used in some countries as analgesics in primary
cancer surgery. Retrospective studies suggest that NSAIDs could reduce breast cancer recurrences. Because NSAIDs also act
on biological mechanisms present in patients with increased adiposity, we aimed at assessing whether the intra-operative
administration of ketorolac or diclofenac would be associated with a reduction of recurrence in patients with elevated body
mass index (BMI).
Methods: We considered two institutional retrospective series of 827 and 1007 patients evaluating the administration of
ketorolac (n ¼ 529 with, n ¼ 298 without) or diclofenac (n ¼ 787 with, n ¼ 220 without). The BMI subgroups were defined as
less than 25 kg/m2 (lean) and 25 or more kg/m2 (overweight and obese). Cumulative incidence estimation of distant
metastases as well as Fine-Gray and Dixon-Simon models was used. These analyses were adjusted for clinico-pathological
variables. All statistical tests were two-sided.
Results: The administration of ketorolac was statistically significantly associated with decreased incidence of distant
recurrences (adjusted hazard ratio [aHR]¼ 0.59, 95% confidence interval [CI] ¼ 0.37 to 0.96, P ¼ .03). In particular, the
association was evident in the high–body mass index (BMI) group of patients (aHR ¼ 0.55, 95% CI ¼ 0.31 to 0.96, P ¼ .04). The
administration of diclofenac was not statistically significantly associated with decreased incidence of distant recurrences,
either in the global population or in the BMI subgroups.
Conclusions: These results show that the intra-operative administration of ketorolac, but not diclofenac, is statistically signif-
icantly associated with a reduction of distant recurrences in patients with increased BMI. Altogether, this study points to a
potentially important repositioning of ketorolac in the intra-operative treatment of patients with elevated BMI that, if pro-
spectively validated, might be as impactful as and cheaper than adjuvant systemic anticancer therapies.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been eval-
uated over the last decades in several, mainly retrospective,
consecutive or case–control studies for their potential role in
preventing breast cancer development and progression (1,2). It
should be noted that most of the studies so far, with some
exceptions, have investigated the chronic use of NSAIDs glob-
ally, without accounting for the pharmacological properties spe-
cific to the different drugs. Additionally, NSAIDs, such as
diclofenac and ketorolac, both COX-1 and -2 inhibitors, have
been introduced over the past decades as effective pain
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relievers in order to reduce the use and dosage of opioids and
their associated adverse events (3,4). This has led to the slow in-
troduction of NSAIDs in the anesthetic scene of cancer surgery
in some countries. Because no specific guidelines have been
proposed as to which specific NSAID should be used, the choice
is generally left at the discretion of the anesthesiologists and
varies therefore from hospital to hospital.
Surgical removal of the primary tumor is a crucial compo-
nent of breast cancer treatment. Nevertheless, it has been
shown to induce metabolic, neuroendocrine, inflammatory, im-
munological, and angiogenic changes (5–10). In this context,
several retrospectives studies showed that the intra-operative
administration of ketorolac was associated with improved can-
cer outcomes in breast, lung, and ovarian cancer (11,12). These
results, although not yet prospectively validated, provocatively
suggested that a single intra-operative administration of ketor-
olac could inhibit the surgery-induced growth of the previously
dormant tumor cells.
Over the last decades, obesity has become a worldwide prob-
lem, not only because of its association with cardiovascular dis-
ease, diabetes mellitus, and hypertension, but also because of
its association with the risk of development and progression of
several cancers (13). In the United States, according to the latest
estimates, 63% of the women are overweight or obese (14).
Increased body mass index (BMI), which is the most commonly
used surrogate for adiposity, has been recognized as a risk fac-
tor for developing breast cancer and has also been associated
with adverse survival, and this especially in postmenopausal
patients with estrogen receptor (ER)–positive breast cancer (15).
Several biological mechanisms have been proposed to explain
this adiposity–breast cancer connection, related mainly to hor-
monal status (estrogens and adipokines), insulin resistance, in-
flammation, and neo-angiogenesis (16,17). Based on these
altered mechanisms, studies have been evaluating, for example,
the potential benefit of treating nondiabetic patients with met-
formin, for which the results of the large randomized adjuvant
National Cancer Institute of Canada (NCIC) Clinical Trials Group
MA32 trial (NCT01101438) should provide evidence as to
whether or not it could provide a survival advantage in early
breast cancer patients (18). However, until now, patients are still
treated in the same way, independently of their BMI.
NSAIDs are acting on biological processes altered both by
primary tumor surgery, as described above, and by adiposity.
For instance, it has been suggested that adiposity could induce
COX-2 expression by the macrophages and tumor cells (19) and
promote angiogenesis (20–22). We therefore hypothesized that
breast cancer patients with an elevated BMI would have an in-
creased benefit from intra-operative NSAIDs. To test this, we
assessed, using two large retrospective institutional cohorts,
whether the intra-operative administration of ketorolac or
diclofenac would be associated with a reduction of distant
recurrences in patients with elevated BMI.
Methods
Study Populations
The institutional retrospective and consecutive “ketorolac” se-
ries of breast cancer patients treated with primary tumor sur-
gery between February 2003 and December 2008 at the
Universite Catholique de Louvain, Brussels, has already been
reported elsewhere (11,23). Previous publications reported a pro-
tective effect on disease recurrence and survival for the use of
NSAIDs (11,23). Of note, no association with cancer outcome
was seen for the other investigated analgesics (sufentanil, keta-
mine, and clonidine). This study was approved by the respective
ethics committee (REF 2010/15MAR/085, No. B40320108384).
Given the different pharmacological properties, we excluded
from this series the few patients who received diclofenac, as
well as those without BMI information available. We considered
827 patients, 529 treated with and 298 without a single dose
(typically 20 mg in patients <60 kg and 30 mg in patients 60
kg) of intra-operative ketorolac (Supplementary Figure 1A and
Supplementary Table 1, available online).
The institutional retrospective and consecutive “diclofenac”
series of breast cancer patients treated with primary tumor sur-
gery between January 2008 and December 2010 at the Institut
Jules Bordet, Brussels, was also considered. Similar to the previ-
ous cohort, the eligibility criteria were diagnosis of invasive
breast cancer, older than age 18 years at diagnosis, no cancer in
the past five years, and no chronic use of an NSAID. This study
was approved by the respective ethics committee (REF AS14/07/
2016, No. 2572). After excluding the patients who did not meet
the eligibility criteria or those without available BMI, 1007
patients remained, 787 treated with intra-operative diclofenac
(75 mg) and 220 without (Supplementary Figure 1B and
Supplementary Table 2, available online).
In both series, distant recurrence was defined as clinical evi-
dence of the development of distant metastases confirmed by
radiological examination(s). BMI was calculated as the weight in
kilograms divided by the square of the height in meters, and
categorized using the World Health Organization classification
(24), and for both cohorts, the BMI at the time of primary surgery
was considered. The BMI subgroups were defined as less than
25 kg/m2 (lean) and 25 or more kg/m2 (overweight and obese).
Statistical Methods
The associations between the NSAID administration and the
clinico-pathological variables were assessed using the Fisher
exact test. Competing risk analysis of distant recurrences was
done by crude cumulative incidence curves to be interpreted as
the cumulative probability of distant metastases as first event
(25) and consistently by Fine and Gray semiparametric models
on subdistribution hazards (26). These analyses were adjusted
for standard clinico-pathological variables: age (<50 or 50
years), tumor size (<2 or 2 cm), nodal status (negative or posi-
tive), grade (1–2 or 3), ER status (negative or positive), human
epidermal growth factor receptor 2 (HER2; negative or positive),
adjuvant chemotherapy (yes or no), adjuvant endocrine therapy
(yes or no), and BMI (<25 or 25 kg/m2).
Analyses for the effect of ketorolac, accounting for the con-
tinuous measurements of age and BMI and their interactions,
were also performed adjusting for the above clinical-
pathological variables, through generalized additive models on
distant metastasis cause-specific hazard.
The Dixon and Simon model for subgroup analysis was also
adopted for the assessment of NSAID effects, following a
Bayesian approach under a skeptical prior hypothesis of no dif-
ference of the effects between the considered subgroups (27).
The median follow-up times of the ketorolac and diclofenac co-
hort were 5.7 and 7.0 years, respectively, as estimated by the re-
verse Kaplan-Meier method. The distant recurrence dynamics
were represented by cause-specific hazard curves, that is, the
rates of recurrence of a specific event at a certain follow-up
time on a monthly basis, estimated by the flexible bshazard
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estimator (28). All statistical tests were two-sided at the .05 sta-
tistical significance level. Statistical analyses were performed
with R v.3.4.1 and its packages cmprsk, mgcv, DSBayes, and
bshazard (29).
Results
Association of BMI and Clinico-pathological Variables in
the Ketorolac and Diclofenac Study Populations
Consistent with previous reports (30), we observed in both
cohorts a statistically significant association between age at di-
agnosis and the administration of the NSAID (Table 1). This can
be explained by the fact that advanced age is a contraindication
for use of NSAIDs. Some additional associations with the ad-
ministration of the respective NSAID were private to one of the
cohorts. These marginal associations can possibly be explained
by the effect of age.
The proportion of overweight and obese patients was com-
parable in the two cohorts, 46.1% and 47.3% in the ketorolac and
diclofenac series, respectively (Table 1), and in line with the pro-
portion of patients with an elevated BMI in Belgium during the
past decade (14). When assessing the associations within the
predefined BMI subgroups (Table 2), the only residual associa-
tions that we observed were the ones with age at diagnosis in
the lean subgroup of the ketorolac cohort and in the two BMI
subgroups of the diclofenac cohort.
Distant Recurrences According to the Administration of
Ketorolac or Diclofenac and BMI
In the ketorolac cohort, 73 distant metastases occurred as the
first event, of which 48 were in the high-BMI group (Figure 1).
The administration of ketorolac was associated with decreased
incidence of distant recurrences both in the unadjusted and ad-
justed analysis (hazard ratio [HR]unadjusted ¼ 0.55, 95% confi-
dence interval [CI] ¼ 0.35 to 0.86, Fine and Gray regression two-
sided Wald test P ¼ .01; HRadjusted ¼ 0.59, 95% CI ¼ 0.37 to 0.96,
P ¼ .03) (Table 3), after accounting for the effect of age, tumor size,
grade, nodal status, ER status, HER2 status, treatment, and BMI.
Subgroup analyses in patients within the predefined BMI
subgroups (<25 and 25 kg/m2) showed that the effect of ketor-
olac was limited to the high-BMI group of patients, both from
the incidence curves and the unadjusted and adjusted regres-
sion analyses (HRunadjusted ¼ 0.51, 95% CI ¼ 0.29 to 0.90, Fine and
Gray regression two-sided Wald test P ¼ .02; HRadjusted ¼ 0.55,
95% CI ¼ 0.31 to 0.96, P ¼ .04) (Table 3). Given the known limita-
tions of subgroup analyses, an additional evaluation was pro-
vided according to the Dixon and Simon model, which provides
estimates of the ketorolac effect, following a Bayesian approach
under a skeptical assumption of no difference between the sub-
groups defined by BMI. Even after a major shrinkage of the ef-
fect of ketorolac in the low-BMI group toward a protective
association, there is still no evidence from the interval esti-
mates for this group, whereas this association of ketorolac is
still evident in the high-BMI group (Supplementary Table 3,
available online). Exploratory analyses on local recurrences did
Table 1. Patient and tumor characteristics of the ketorolac and diclofenac series according to the administration of the respective NSAID
Characteristics
Ketorolac series Diclofenac series
All No. (%) No K No. (%) K No. (%) P* All No. (%) No D No. (%) D No. (%) P*
Age, y
<50 197 (23.8) 52 (17.4) 145 (27.4) .001 290 (28.8) 36 (16.4) 254 (32.3) <.001
50 630 (76.2) 246 (82.6) 384 (72.6) 717 (71) 184 (83.6) 533 (67.7)
BMI, kg/m2
<25 446 (53.9) 130 (43.6) 316 (59.7) <.001 531 (52.7) 110 (50.0) 421 (53.5) .36
25 381 (46.1) 168 (56.4) 213 (40.3) 476 (47.3) 110 (50.0) 366 (46.5)
Tumor size, cm
<2 466 (56.4) 153 (51.3) 313 (59.3) .03 634 (63.5) 136 (62.4) 498 (63.8) .69
2 360 (43.6) 145 (48.7) 215 (40.7) 364 (36.5) 82 (37.6) 282 (36.2)
Unknown 1 – 1 9 2 7
Grade
1 129 (16.9) 46 (16.7) 83 (17.0) .97 192 (19.1) 48 (21.9) 144 (18.3) .37
2 281 (36.8) 100 (36.4) 181 (37.0) 518 (51.5) 113 (51.6) 405 (51.5)
3 354 (46.3) 129 (46.9) 225 (46.0) 295 (29.4) 58 (26.5) 237 (30.2)
Unknown 63 23 40 2 1 1
Nodal status
Negative 505 (65.8) 173 (63.1) 332 (67.2) .27 699 (69.4) 168 (76.4) 531 (67.5) .01
Positive 263 (34.2) 101 (36.9) 162 (32.8) 308 (30.6) 52 (23.6) 256 (32.5)
Unknown 59 24 35 – – –
ER status
Negative 141 (17.4) 50 (17.1) 91 (17.6) .92 161 (16.0) 27 (12.3) 134 (17.1) .10
Positive 670 (82.6) 243 (82.9) 427 (82.4) 843 (84.0) 192 (87.7) 651 (82.9)
Unknown 16 5 11 3 1 2
HER2 status
Negative 577 (76.7) 210 (78.1) 367 (76.0) .53 802 (79.6) 180 (81.8) 622 (79.0) .39
Positive 175 (23.3) 59 (21.9) 116 (24.0) 205 (20.4) 40 (18.2) 165 (21.0)
Unknown 75 29 46 – – –
*Two-sided Fisher exact test P values. BMI ¼ body mass index; D ¼ diclofenac; ER ¼ estrogen receptor; HER2 ¼ human epidermal growth factor receptor 2; K ¼ ketorolac;
NSAID ¼ nonsteroidal anti-inflammatory drug.
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not support any association of ketorolac in the global population
or in the BMI subgroups. However, these latter analyses were lim-
ited by the small number of events and should therefore be taken
with caution (data not shown). In addition, the exploratory analy-
sis of the modifying role of age and BMI, both considered as con-
tinuous variables, on the effect of ketorolac was consistent with
the above results, showing major evidence in the group of over-
weight patients with older than age 50 years (Supplementary
Figure 2 and Supplementary Table 4, available online).
To evaluate the potential confounding effect of the other
drugs administered in the operative setting, especially opioids
such as sufentanil and piritramide, we conducted exploratory
adjusted analyses including each of these drugs for the subset
of patients for which this information had been recorded (n ¼
272 for sufentanil, clonidine, and ketamine and 251 for piritra-
mide). The administration of ketorolac was associated with a
decrease in the administration of sufentanil (odds ratio [OR] ¼
0.30, 95% CI ¼ 0.15 to 0.56, two-sided Fisher exact test P < .001)
Table 2. Patient and tumor characteristics according to the administration of the respective NSAID and BMI category
Characteristics All No. (%) No K No. (%) K No. (%) P* All No. (%) No D No. (%) D No. (%) P*
Patients with BMI <25 kg/m2
Age, y
<50 128 (28.7) 28 (21.5) 100 (31.6) .04 192 (36.2) 24 (21.8) 168 (39.9) <.001
50 318 (71.3) 102 (78.5) 216 (68.4) 339 (63.8) 86 (78.2) 253 (60.1)
Tumor size, cm
<2 276 (61.9) 77 (59.2) 199 (63.0) .52 353 (67.1) 67 (61.5) 286 (68.6) .17
2 170 (38.1) 53 (40.8) 117 (37.0) 173 (32.9) 42 (38.5) 131 (31.4)
Unknown    5 1 4
Grade
1 78 (18.8) 24 (20.5) 54 (18.2) .62 116 (21.9) 29 (26.4) 87 (20.7) .34
2 156 (37.7) 40 (34.2) 116 (39.1) 266 (50.2) 55 (50.0) 211 (50.2)
3 180 (43.5) 53 (45.3) 127 (42.8) 148 (27.9) 26 (23.6) 122 (29.0)
Unknown 32 13 19 1  1
Nodal status
Negative 291 (70.0) 86 (72.3) 205 (69.0) .56 371 (69.9) 84 (76.4) 287 (68.2) .10
Positive 125 (30.0) 33 (27.7) 92 (31.0) 160 (30.1) 26 (23.6) 134 (31.8)
Unknown 30 11 19   
ER status
Negative 81 (18.6) 26 (20.5) 55 (17.8) .50 98 (18.5) 17 (15.6) 81 (19.3) .41
Positive 355 (81.4) 101 (79.5) 254 (82.2) 431 (81.5) 92 (84.4) 339 (80.7)
Unknown 10 3 7 2 1 1
HER2 status
Negative 297 (74.2) 87 (77.7) 209 (72.8) .37 427 (80.4) 95 (86.4) 332 (78.9) .08
Positive 103 (25.8) 25 (22.3) 78 (27.2) 104 (19.6) 15 (13.6) 89 (21.1)
Unknown 47 18 29   
Patients with BMI 25 kg/m2
Age, y
<50 69 (18.1) 24 (14.3) 45 (21.1) .11 98 (20.6) 12 (10.9) 86 (23.5) .004
50 312 (81.9) 144 (85.7) 168 (78.9) 378 (79.4) 98 (89.1) 280 (76.5)
Tumor size, cm
<2 190 (50.0) 76 (45.2) 114 (53.8) .12 281 (59.5) 69 (63.3) 212 (58.4) .38
2 190 (50.0) 92 (54.8) 98 (46.2) 191 (40.5) 40 (36.7) 151 (41.6)
Unknown 1  1 4 1 3
Grade
1 51 (14.6) 22 (13.9) 29 (15.1) .74 76 (16.0) 19 (17.4) 57 (15.6) .85
2 125 (35.7) 60 (38.0) 65 (33.9) 253 (53.1) 58 (53.2) 194 (53.0)
3 174 (49.7) 76 (48.1) 98 (51.0) 147 (30.9) 32 (29.4) 115 (31.4)
Unknown 31 10 21 1 1 
Nodal status
Negative 214 (60.8) 87 (56.1) 127 (64.5) .12 328 (68.9) 84 (76.4) 244 (66.7) .06
Positive 138 (39.2) 68 (43.9) 70 (35.5) 149 (31.1) 26 (23.6) 122 (33.3)
Unknown 29 13 16   
ER status
Negative 60 (16.0) 24 (14.5) 36 (17.2) .48 63 (13.3) 10 (9.1) 53 (14.5) .15
Positive 315 (84.0) 142 (85.5) 173 (82.8) 412 (86.7) 100 (90.9) 312 (85.5)
Unknown 6 2 4 1  1
HER2 status
Negative 281 (79.6) 123 (78.3) 158 (80.6) .60 375 (78.8) 85 (77.3) 290 (79.2) .69
Positive 72 (20.4) 34 (21.7) 38 (19.4) 101 (21.2) 25 (22.7) 76 (20.8)
Unknown 28 11 17   
*Two-sided Fisher exact test P values. BMI ¼ body mass index; D ¼ diclofenac; ER ¼ estrogen receptor; HER2 ¼ human epidermal growth factor receptor 2; K ¼ ketorolac;
NSAID ¼ nonsteroidal anti-inflammatory drug.
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but not piritramide (OR ¼ 0.75, 95% CI ¼ 0.43 to 1.31, P ¼ .30; data
not shown). In all models, ketorolac remained statistically sig-
nificantly associated with a reduction of distant disease recur-
rences, therefore, against a possible confounding effect of the
other drugs (Supplementary Figure 3, available online).
We further evaluated the recurrence patterns over time for
the two BMI subgroups. These analyses revealed that the ad-
ministration of ketorolac was clearly associated with a reduc-
tion of the early metastases in all patients and in the high-BMI
subgroup (Figure 2).
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Figure 1. Crude cumulative incidence of distant metastases according treatment. Ketorolac (A–C) and diclofenac (D–F) administration in all patients (A, D), in patients
with BMI <25kg/m2 (B, E) and BMI 25kg/m2 (C, F). Two-sided Gray’s test P values are reported. BMI ¼ body mass index; DM ¼ distant metastasis.
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Figure 2. Cause-specific hazard estimates for distant metastases over time according to BMI in the ketorolac cohort. All patients (A), BMI <25 kg/m2 (B), and
BMI 25 kg/m2 (C). Estimates were obtained by the bshazard method. BMI ¼ body mass index; DM ¼ distant metastasis.
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In the diclofenac cohort, 79 distant metastases occurred as
the first event, of which 41 were in the high-BMI group. The ad-
ministration of diclofenac was not associated with decreased
incidence of distant recurrences in the global population,
neither in the unadjusted or adjusted analyses (HRunadjusted ¼
1.39, 95% CI ¼ 0.77 to 2.51, Fine and Gray regression two-sided
Wald test P ¼ .28; HRadjusted ¼ 1.04, 95% CI ¼ 0.58 to 1.87, P ¼ .88)
(Table 3). We also did not observe any association with distant
events in the BMI subgroups (Table 3).
Discussion
So far, few treatment modalities focusing on the biological char-
acteristics of breast cancer patients with increased BMI have
been evaluated. In this study, we explored the impact of two dif-
ferent nonselective NSAIDs administered intra-operatively on
disease recurrence after primary tumor surgery. Our results
showed that ketorolac was mainly associated with a reduction
in disease recurrence in the group of patients with increased
BMI, but without excluding, so far, an effect also in normal BMI
patients. The exploratory analyses that considered age and BMI
as continuous variables suggested that this association could be
more pronounced for overweight patients older than age 50
years.
As opposed to ketorolac, no association with disease recur-
rence was observed for diclofenac. Actually, this difference
might be explained by an important additional pharmacological
property recently uncovered for ketorolac. Indeed, besides the
selective activity of the S-enantiomer against COX-1 and -2,
which is the basis of the US Food and Drug Administration ap-
proval for pain management, an unexpected GTPase inhibitor
activity against RAC1 and CDC42 has recently been attributed to
the R-enantiomer (30–32). RAC1 and CDC42 are members of the
Ras-homologous (Rho) family of small GTPases, involved in cell
motility, adhesion, and invasion (33). Importantly, RAC1 and
CDC42 have been shown to be upregulated by leptin, one of the
two adipokines abnormally secreted in case of overweight and
obesity, in colorectal and ovarian cancer (34,35). Specifically, the
authors demonstrated that leptin was capable of inducing new
focal adhesion complexes by activating the RhoA signaling
pathway (35). Therefore, the fact that only ketorolac but not
diclofenac was associated with a statistically significant reduc-
tion of distant recurrences in patients with elevated BMI could
possibly be explained by the specific Rho GTPase inhibitory ef-
fect of the R-enantiomer of ketorolac, which is absent in diclofe-
nac (Supplementary Figure 4, available online). Also of interest
is the demonstration that the half-life of the R-enantiomer is
twice that of the S-enantiomer of ketorolac, and it has conse-
quently been shown that the R-enantiomer is enriched in serum
(30,36). It is, however, unclear whether the anti-inflammatory
pharmacological property of the S-enantiomer is still playing a
role in preventing distant recurrences or whether the effect is
fully played by the R-enantiomer. This should be explored using
the enantiopure drugs. Of note, the only other NSAID for which
the Rho GTPase inhibitory effect of the R-enantiomer has been
demonstrated is naproxen (12). The effect seen with ketorolac
could also potentially and partially be linked to the fact that the
intra-operative administration of ketorolac is less immunosup-
pressive than the administration of other analgesics, as recently
demonstrated by Bakr et al. (37).
While it might appear surprising that a single dose of ketoro-
lac is associated with a reduction of distant disease recurrence,
this is most probably due to the timing of the administration,
the intra-operative setting at the initiation of surgery. Indeed,
the surgical removal of the primary tumor has been shown to
disturb the homeostasis of the disease at the systemic level and
to possibly trigger the development of early recurrences (38,39).
Indeed, the “primary metastases–host” combination should be
viewed as a complex system, where the focalized action of pri-
mary tumor surgical removal is able to prompt a long-lasting ef-
fect on the course of the disease by disrupting the homeostatic
stability (38,39). It is therefore reasonable that impinging on
destabilizing processes right in this time may have definite con-
sequences. Complex system dynamics are exquisitely sensitive
on initial conditions, and, therefore, changes occurring in criti-
cal early times may be able to cause major changes in system
evolution (40). In this context, it is worth reporting the old
Scandinavian randomized clinical trial where one single course
of peri-operative cyclophosphamide resulted in a statistically
significant improvement in disease-free survival at 17.1 years of
follow-up, while the same course given two to four weeks after
mastectomy did not provide any benefit (41).
The time-dependent analyses revealed that ketorolac was
specifically associated with a reduction of early recurrences,
suggesting that it could exert an excellent distant control on the
surgically induced awakening of already disseminated subclini-
cal metastatic foci. These data therefore emphasize that anes-
thesia can have in addition to its expected immediate effects,
also consequences on disease evolution. Consequently, this ap-
proach could be extremely appealing for parts of the globe
where obesity has been strongly increasing during the last de-
cade and where resources for cancer treatment are scarce. Of
Table 3. Results from Fine and Gray regression model, with estimated distant metastasis hazard ratios for those receiving vs not receiving
NSAIDs, in all patients and in the two BMI subgroups*
NSAID
All BMI < 25 BMI  25
HR (95% CI) P† HR (95% CI) P† HR (95% CI) P†
Ketorolac
Unadjusted 0.55 (0.35 to 0.86) .01 0.84 (0.37 to 1.94) .68 0.51 (0.29 to 0.90) .02
Adjusted 0.59 (0.37 to 0.96) .03 0.78 (0.29 to 2.05) .61 0.55 (0.31 to 0.96) .04
Diclofenac
Unadjusted 1.39 (0.77 to 2.51) .28 1.66 (0.65 to 4.24) .29 1.24 (0.58 to 2.69) .58
Adjusted 1.04 (0.58 to 1.87) .88 1.29 (0.53 to 3.12) .57 0.89 (0.39 to 2.02) .77
*Adjusted model includes age (<50 or 50 years), tumor size (<2 or 2 cm), nodal status (negative or positive), grade (1–2 or 3), estrogen receptor status (negative or pos-
itive), human epidermal growth factor receptor 2 status (negative or positive), adjuvant chemotherapy (no or yes), adjuvant endocrine therapy (no or yes) and BMI (<25
or 25 kg/m2). BMI ¼ body mass index; CI ¼ confidence interval; HR ¼ hazard ratio; NSAID ¼ nonsteroidal anti-inflammatory drug.
†Two-sided Wald test P values.
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interest, as previously reported for breast cancer (11,23), the
intra-operative role of ketorolac had also been demonstrated in
lung and ovarian cancer patients (42,43). Forget et al. reported
an independent beneficial effect of NSAID administration
(mainly ketorolac) at the beginning of surgery on distant dis-
ease–free survival in an institutional series of 255 lung cancer
patients (42). Guo et al. further showed in their retrospective
study, which included 123 ovarian cancer patients, that the
peri-operative use of ketorolac was associated with a statisti-
cally significant reduction of ovarian cancer–specific mortality
(43). We may therefore hypothesize that also in other cancer
types ketorolac may play a role in reducing disease recurrence
specifically in patients with increased adiposity.
To conclude, while this study is limited by its retrospective
nature and many questions regarding the intra-operative use of
ketorolac still need to be answered, such as the optimal timing,
duration, dose, and combination with other analgesics, it sug-
gests a potentially important repositioning of ketorolac in the
intra-operative treatment of breast cancer patients with ele-
vated BMI and points to the need for a prospective confirmatory
randomized trial.
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